The global FIC Dual-target Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on FIC Dual-target Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

FIC (First in Class) refers to a drug that is first-in-class and is created by gradually synthesizing candidate compounds from scratch by finding new drug targets, mechanisms of action, and molecular structures. Through repeated trials and screening, the drug is ultimately found to meet the requirements of both therapeutic effects and human safety (tolerance, pharmacokinetics).

The North American market for FIC Dual-target Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for FIC Dual-target Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of FIC Dual-target Drugs include Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global FIC Dual-target Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding FIC Dual-target Drugs. The FIC Dual-target Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global FIC Dual-target Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist FIC Dual-target Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of FIC Dual-target Drugs Market Report

Report Metric	Details
Report Name	FIC Dual-target Drugs Market
Segment by Type	EZH2/HSP90 Targets GPX4/CDK Targets Polθ/PARP Targets Others
by Application	Hospital Clinic Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, Eli Lilly, Agios, Boehringer Ingelheim, Gilead, Mallinckrodt, Phathom, Dermavant Sciences, Polarean lmaging, Marinus
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for FIC Dual-target Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines FIC Dual-target Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the FIC Dual-target Drugs Market report?

Ans: The main players in the FIC Dual-target Drugs Market are Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, Eli Lilly, Agios, Boehringer Ingelheim, Gilead, Mallinckrodt, Phathom, Dermavant Sciences, Polarean lmaging, Marinus

What are the Application segmentation covered in the FIC Dual-target Drugs Market report?

Ans: The Applications covered in the FIC Dual-target Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the FIC Dual-target Drugs Market report?

Ans: The Types covered in the FIC Dual-target Drugs Market report are EZH2/HSP90 Targets, GPX4/CDK Targets, Polθ/PARP Targets, Others

1 FIC Dual-target Drugs Market Overview

1.1 Product Definition

1.2 FIC Dual-target Drugs by Type

1.2.1 Global FIC Dual-target Drugs Market Value by Type: 2025 vs 2032

1.2.2 EZH2/HSP90 Targets

1.2.3 GPX4/CDK Targets

1.2.4 Polθ/PARP Targets

1.2.5 Others

1.3 FIC Dual-target Drugs by Application

1.3.1 Global FIC Dual-target Drugs Market Value by Application: 2025 vs 2032

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Global FIC Dual-target Drugs Market Size Estimates and Forecasts

1.4.1 Global FIC Dual-target Drugs Revenue 2021–2032

1.4.2 Global FIC Dual-target Drugs Sales 2021–2032

1.4.3 Global FIC Dual-target Drugs Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 FIC Dual-target Drugs Market Competition by Manufacturers

2.1 Global FIC Dual-target Drugs Sales Market Share by Manufacturers (2021–2026)

2.2 Global FIC Dual-target Drugs Revenue Market Share by Manufacturers (2021–2026)

2.3 Global FIC Dual-target Drugs Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of FIC Dual-target Drugs, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of FIC Dual-target Drugs, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of FIC Dual-target Drugs, Product Types and Applications

2.7 Global Key Manufacturers of FIC Dual-target Drugs, Date of Entry into the Industry

2.8 Global FIC Dual-target Drugs Market Competitive Situation and Trends

2.8.1 Global FIC Dual-target Drugs Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global FIC Dual-target Drugs Players Market Share by Revenue

2.8.3 Global FIC Dual-target Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global FIC Dual-target Drugs Market Scenario by Region

3.1 Global FIC Dual-target Drugs Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global FIC Dual-target Drugs Sales by Region: 2021–2032

3.2.1 Global FIC Dual-target Drugs Sales by Region: 2021–2026

3.2.2 Global FIC Dual-target Drugs Sales by Region: 2027–2032

3.3 Global FIC Dual-target Drugs Revenue by Region: 2021–2032

3.3.1 Global FIC Dual-target Drugs Revenue by Region: 2021–2026

3.3.2 Global FIC Dual-target Drugs Revenue by Region: 2027–2032

3.4 North America FIC Dual-target Drugs Market Facts & Figures by Country

3.4.1 North America FIC Dual-target Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America FIC Dual-target Drugs Sales by Country (2021–2032)

3.4.3 North America FIC Dual-target Drugs Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe FIC Dual-target Drugs Market Facts & Figures by Country

3.5.1 Europe FIC Dual-target Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe FIC Dual-target Drugs Sales by Country (2021–2032)

3.5.3 Europe FIC Dual-target Drugs Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific FIC Dual-target Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific FIC Dual-target Drugs Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific FIC Dual-target Drugs Sales by Region (2021–2032)

3.6.3 Asia Pacific FIC Dual-target Drugs Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America FIC Dual-target Drugs Market Facts & Figures by Country

3.7.1 Latin America FIC Dual-target Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America FIC Dual-target Drugs Sales by Country (2021–2032)

3.7.3 Latin America FIC Dual-target Drugs Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa FIC Dual-target Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa FIC Dual-target Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa FIC Dual-target Drugs Sales by Country (2021–2032)

3.8.3 Middle East and Africa FIC Dual-target Drugs Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global FIC Dual-target Drugs Sales by Type (2021–2032)

4.1.1 Global FIC Dual-target Drugs Sales by Type (2021–2026)

4.1.2 Global FIC Dual-target Drugs Sales by Type (2027–2032)

4.1.3 Global FIC Dual-target Drugs Sales Market Share by Type (2021–2032)

4.2 Global FIC Dual-target Drugs Revenue by Type (2021–2032)

4.2.1 Global FIC Dual-target Drugs Revenue by Type (2021–2026)

4.2.2 Global FIC Dual-target Drugs Revenue by Type (2027–2032)

4.2.3 Global FIC Dual-target Drugs Revenue Market Share by Type (2021–2032)

4.3 Global FIC Dual-target Drugs Price by Type (2021–2032)

5 Segment by Application

5.1 Global FIC Dual-target Drugs Sales by Application (2021–2032)

5.1.1 Global FIC Dual-target Drugs Sales by Application (2021–2026)

5.1.2 Global FIC Dual-target Drugs Sales by Application (2027–2032)

5.1.3 Global FIC Dual-target Drugs Sales Market Share by Application (2021–2032)

5.2 Global FIC Dual-target Drugs Revenue by Application (2021–2032)

5.2.1 Global FIC Dual-target Drugs Revenue by Application (2021–2026)

5.2.2 Global FIC Dual-target Drugs Revenue by Application (2027–2032)

5.2.3 Global FIC Dual-target Drugs Revenue Market Share by Application (2021–2032)

5.3 Global FIC Dual-target Drugs Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Company Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Pfizer FIC Dual-target Drugs Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 Johnson & Johnson

6.2.1 Johnson & Johnson Company Information

6.2.2 Johnson & Johnson Description and Business Overview

6.2.3 Johnson & Johnson FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Johnson & Johnson FIC Dual-target Drugs Product Portfolio

6.2.5 Johnson & Johnson Recent Developments/Updates

6.3 Merck

6.3.1 Merck Company Information

6.3.2 Merck Description and Business Overview

6.3.3 Merck FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Merck FIC Dual-target Drugs Product Portfolio

6.3.5 Merck Recent Developments/Updates

6.4 Roche

6.4.1 Roche Company Information

6.4.2 Roche Description and Business Overview

6.4.3 Roche FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Roche FIC Dual-target Drugs Product Portfolio

6.4.5 Roche Recent Developments/Updates

6.5 Novartis

6.5.1 Novartis Company Information

6.5.2 Novartis Description and Business Overview

6.5.3 Novartis FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Novartis FIC Dual-target Drugs Product Portfolio

6.5.5 Novartis Recent Developments/Updates

6.6 BMS

6.6.1 BMS Company Information

6.6.2 BMS Description and Business Overview

6.6.3 BMS FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 BMS FIC Dual-target Drugs Product Portfolio

6.6.5 BMS Recent Developments/Updates

6.7 ImmunoGen

6.7.1 ImmunoGen Company Information

6.7.2 ImmunoGen Description and Business Overview

6.7.3 ImmunoGen FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 ImmunoGen FIC Dual-target Drugs Product Portfolio

6.7.5 ImmunoGen Recent Developments/Updates

6.8 Sanofi

6.8.1 Sanofi Company Information

6.8.2 Sanofi Description and Business Overview

6.8.3 Sanofi FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Sanofi FIC Dual-target Drugs Product Portfolio

6.8.5 Sanofi Recent Developments/Updates

6.9 Immunocore

6.9.1 Immunocore Company Information

6.9.2 Immunocore Description and Business Overview

6.9.3 Immunocore FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Immunocore FIC Dual-target Drugs Product Portfolio

6.9.5 Immunocore Recent Developments/Updates

6.10 Genentech

6.10.1 Genentech Company Information

6.10.2 Genentech Description and Business Overview

6.10.3 Genentech FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Genentech FIC Dual-target Drugs Product Portfolio

6.10.5 Genentech Recent Developments/Updates

6.11 Eli Lilly

6.11.1 Eli Lilly Company Information

6.11.2 Eli Lilly Description and Business Overview

6.11.3 Eli Lilly FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Eli Lilly FIC Dual-target Drugs Product Portfolio

6.11.5 Eli Lilly Recent Developments/Updates

6.12 Agios

6.12.1 Agios Company Information

6.12.2 Agios Description and Business Overview

6.12.3 Agios FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 Agios FIC Dual-target Drugs Product Portfolio

6.12.5 Agios Recent Developments/Updates

6.13 Boehringer Ingelheim

6.13.1 Boehringer Ingelheim Company Information

6.13.2 Boehringer Ingelheim Description and Business Overview

6.13.3 Boehringer Ingelheim FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.13.4 Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio

6.13.5 Boehringer Ingelheim Recent Developments/Updates

6.14 Gilead

6.14.1 Gilead Company Information

6.14.2 Gilead Description and Business Overview

6.14.3 Gilead FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.14.4 Gilead FIC Dual-target Drugs Product Portfolio

6.14.5 Gilead Recent Developments/Updates

6.15 Mallinckrodt

6.15.1 Mallinckrodt Company Information

6.15.2 Mallinckrodt Description and Business Overview

6.15.3 Mallinckrodt FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.15.4 Mallinckrodt FIC Dual-target Drugs Product Portfolio

6.15.5 Mallinckrodt Recent Developments/Updates

6.16 Phathom

6.16.1 Phathom Company Information

6.16.2 Phathom Description and Business Overview

6.16.3 Phathom FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.16.4 Phathom FIC Dual-target Drugs Product Portfolio

6.16.5 Phathom Recent Developments/Updates

6.17 Dermavant Sciences

6.17.1 Dermavant Sciences Company Information

6.17.2 Dermavant Sciences Description and Business Overview

6.17.3 Dermavant Sciences FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.17.4 Dermavant Sciences FIC Dual-target Drugs Product Portfolio

6.17.5 Dermavant Sciences Recent Developments/Updates

6.18 Polarean lmaging

6.18.1 Polarean lmaging Company Information

6.18.2 Polarean lmaging Description and Business Overview

6.18.3 Polarean lmaging FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.18.4 Polarean lmaging FIC Dual-target Drugs Product Portfolio

6.18.5 Polarean lmaging Recent Developments/Updates

6.19 Marinus

6.19.1 Marinus Company Information

6.19.2 Marinus Description and Business Overview

6.19.3 Marinus FIC Dual-target Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.19.4 Marinus FIC Dual-target Drugs Product Portfolio

6.19.5 Marinus Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 FIC Dual-target Drugs Industry Chain Analysis

7.2 FIC Dual-target Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 FIC Dual-target Drugs Production Mode & Process Analysis

7.4 FIC Dual-target Drugs Sales and Marketing

7.4.1 FIC Dual-target Drugs Sales Channels

7.4.2 FIC Dual-target Drugs Distributors

7.5 FIC Dual-target Drugs Customer Analysis

8 FIC Dual-target Drugs Market Dynamics

8.1 FIC Dual-target Drugs Industry Trends

8.2 FIC Dual-target Drugs Market Drivers

8.3 FIC Dual-target Drugs Market Challenges

8.4 FIC Dual-target Drugs Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global FIC Dual-target Drugs Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global FIC Dual-target Drugs Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global FIC Dual-target Drugs Market Competitive Situation by Manufacturers in 2025

Table 4. Global FIC Dual-target Drugs Sales (K Units) of Key Manufacturers (2021–2026)

Table 5. Global FIC Dual-target Drugs Sales Market Share by Manufacturers (2021–2026)

Table 6. Global FIC Dual-target Drugs Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global FIC Dual-target Drugs Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market FIC Dual-target Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of FIC Dual-target Drugs, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of FIC Dual-target Drugs, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of FIC Dual-target Drugs, Product Types and Applications

Table 12. Global Key Manufacturers of FIC Dual-target Drugs, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global FIC Dual-target Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on FIC Dual-target Drugs Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global FIC Dual-target Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global FIC Dual-target Drugs Sales by Region (K Units), 2021–2026

Table 18. Global FIC Dual-target Drugs Sales Market Share by Region (2021–2026)

Table 19. Global FIC Dual-target Drugs Sales by Region (K Units), 2027–2032

Table 20. Global FIC Dual-target Drugs Sales Market Share by Region (2027–2032)

Table 21. Global FIC Dual-target Drugs Revenue by Region (US$ Million), 2021–2026

Table 22. Global FIC Dual-target Drugs Revenue Market Share by Region (2021–2026)

Table 23. Global FIC Dual-target Drugs Revenue by Region (US$ Million), 2027–2032

Table 24. Global FIC Dual-target Drugs Revenue Market Share by Region (2027–2032)

Table 25. North America FIC Dual-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America FIC Dual-target Drugs Sales by Country (K Units), 2021–2026

Table 27. North America FIC Dual-target Drugs Sales by Country (K Units), 2027–2032

Table 28. North America FIC Dual-target Drugs Revenue by Country (US$ Million), 2021–2026

Table 29. North America FIC Dual-target Drugs Revenue by Country (US$ Million), 2027–2032

Table 30. Europe FIC Dual-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe FIC Dual-target Drugs Sales by Country (K Units), 2021–2026

Table 32. Europe FIC Dual-target Drugs Sales by Country (K Units), 2027–2032

Table 33. Europe FIC Dual-target Drugs Revenue by Country (US$ Million), 2021–2026

Table 34. Europe FIC Dual-target Drugs Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific FIC Dual-target Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific FIC Dual-target Drugs Sales by Region (K Units), 2021–2026

Table 37. Asia Pacific FIC Dual-target Drugs Sales by Region (K Units), 2027–2032

Table 38. Asia Pacific FIC Dual-target Drugs Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific FIC Dual-target Drugs Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America FIC Dual-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America FIC Dual-target Drugs Sales by Country (K Units), 2021–2026

Table 42. Latin America FIC Dual-target Drugs Sales by Country (K Units), 2027–2032

Table 43. Latin America FIC Dual-target Drugs Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America FIC Dual-target Drugs Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa FIC Dual-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa FIC Dual-target Drugs Sales by Country (K Units), 2021–2026

Table 47. Middle East and Africa FIC Dual-target Drugs Sales by Country (K Units), 2027–2032

Table 48. Middle East and Africa FIC Dual-target Drugs Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa FIC Dual-target Drugs Revenue by Country (US$ Million), 2027–2032

Table 50. Global FIC Dual-target Drugs Sales (K Units) by Type (2021–2026)

Table 51. Global FIC Dual-target Drugs Sales (K Units) by Type (2027–2032)

Table 52. Global FIC Dual-target Drugs Sales Market Share by Type (2021–2026)

Table 53. Global FIC Dual-target Drugs Sales Market Share by Type (2027–2032)

Table 54. Global FIC Dual-target Drugs Revenue (US$ Million) by Type (2021–2026)

Table 55. Global FIC Dual-target Drugs Revenue (US$ Million) by Type (2027–2032)

Table 56. Global FIC Dual-target Drugs Revenue Market Share by Type (2021–2026)

Table 57. Global FIC Dual-target Drugs Revenue Market Share by Type (2027–2032)

Table 58. Global FIC Dual-target Drugs Price (US$/Unit) by Type (2021–2026)

Table 59. Global FIC Dual-target Drugs Price (US$/Unit) by Type (2027–2032)

Table 60. Global FIC Dual-target Drugs Sales (K Units) by Application (2021–2026)

Table 61. Global FIC Dual-target Drugs Sales (K Units) by Application (2027–2032)

Table 62. Global FIC Dual-target Drugs Sales Market Share by Application (2021–2026)

Table 63. Global FIC Dual-target Drugs Sales Market Share by Application (2027–2032)

Table 64. Global FIC Dual-target Drugs Revenue (US$ Million) by Application (2021–2026)

Table 65. Global FIC Dual-target Drugs Revenue (US$ Million) by Application (2027–2032)

Table 66. Global FIC Dual-target Drugs Revenue Market Share by Application (2021–2026)

Table 67. Global FIC Dual-target Drugs Revenue Market Share by Application (2027–2032)

Table 68. Global FIC Dual-target Drugs Price (US$/Unit) by Application (2021–2026)

Table 69. Global FIC Dual-target Drugs Price (US$/Unit) by Application (2027–2032)

Table 70. Pfizer Company Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 73. Pfizer FIC Dual-target Drugs Product

Table 74. Pfizer Recent Developments/Updates

Table 75. Johnson & Johnson Company Information

Table 76. Johnson & Johnson Description and Business Overview

Table 77. Johnson & Johnson FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 78. Johnson & Johnson FIC Dual-target Drugs Product

Table 79. Johnson & Johnson Recent Developments/Updates

Table 80. Merck Company Information

Table 81. Merck Description and Business Overview

Table 82. Merck FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 83. Merck FIC Dual-target Drugs Product

Table 84. Merck Recent Developments/Updates

Table 85. Roche Company Information

Table 86. Roche Description and Business Overview

Table 87. Roche FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 88. Roche FIC Dual-target Drugs Product

Table 89. Roche Recent Developments/Updates

Table 90. Novartis Company Information

Table 91. Novartis Description and Business Overview

Table 92. Novartis FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 93. Novartis FIC Dual-target Drugs Product

Table 94. Novartis Recent Developments/Updates

Table 95. BMS Company Information

Table 96. BMS Description and Business Overview

Table 97. BMS FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 98. BMS FIC Dual-target Drugs Product

Table 99. BMS Recent Developments/Updates

Table 100. ImmunoGen Company Information

Table 101. ImmunoGen Description and Business Overview

Table 102. ImmunoGen FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 103. ImmunoGen FIC Dual-target Drugs Product

Table 104. ImmunoGen Recent Developments/Updates

Table 105. Sanofi Company Information

Table 106. Sanofi Description and Business Overview

Table 107. Sanofi FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 108. Sanofi FIC Dual-target Drugs Product

Table 109. Sanofi Recent Developments/Updates

Table 110. Immunocore Company Information

Table 111. Immunocore Description and Business Overview

Table 112. Immunocore FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 113. Immunocore FIC Dual-target Drugs Product

Table 114. Immunocore Recent Developments/Updates

Table 115. Genentech Company Information

Table 116. Genentech Description and Business Overview

Table 117. Genentech FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 118. Genentech FIC Dual-target Drugs Product

Table 119. Genentech Recent Developments/Updates

Table 120. Eli Lilly Company Information

Table 121. Eli Lilly Description and Business Overview

Table 122. Eli Lilly FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 123. Eli Lilly FIC Dual-target Drugs Product

Table 124. Eli Lilly Recent Developments/Updates

Table 125. Agios Company Information

Table 126. Agios Description and Business Overview

Table 127. Agios FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 128. Agios FIC Dual-target Drugs Product

Table 129. Agios Recent Developments/Updates

Table 130. Boehringer Ingelheim Company Information

Table 131. Boehringer Ingelheim Description and Business Overview

Table 132. Boehringer Ingelheim FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 133. Boehringer Ingelheim FIC Dual-target Drugs Product

Table 134. Boehringer Ingelheim Recent Developments/Updates

Table 135. Gilead Company Information

Table 136. Gilead Description and Business Overview

Table 137. Gilead FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 138. Gilead FIC Dual-target Drugs Product

Table 139. Gilead Recent Developments/Updates

Table 140. Mallinckrodt Company Information

Table 141. Mallinckrodt Description and Business Overview

Table 142. Mallinckrodt FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 143. Mallinckrodt FIC Dual-target Drugs Product

Table 144. Mallinckrodt Recent Developments/Updates

Table 145. Phathom Company Information

Table 146. Phathom Description and Business Overview

Table 147. Phathom FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 148. Phathom FIC Dual-target Drugs Product

Table 149. Phathom Recent Developments/Updates

Table 150. Dermavant Sciences Company Information

Table 151. Dermavant Sciences Description and Business Overview

Table 152. Dermavant Sciences FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 153. Dermavant Sciences FIC Dual-target Drugs Product

Table 154. Dermavant Sciences Recent Developments/Updates

Table 155. Polarean lmaging Company Information

Table 156. Polarean lmaging Description and Business Overview

Table 157. Polarean lmaging FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 158. Polarean lmaging FIC Dual-target Drugs Product

Table 159. Polarean lmaging Recent Developments/Updates

Table 160. Marinus Company Information

Table 161. Marinus Description and Business Overview

Table 162. Marinus FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 163. Marinus FIC Dual-target Drugs Product

Table 164. Marinus Recent Developments/Updates

Table 165. Key Raw Materials Lists

Table 166. Raw Materials Key Suppliers Lists

Table 167. FIC Dual-target Drugs Distributors List

Table 168. FIC Dual-target Drugs Customers List

Table 169. FIC Dual-target Drugs Market Trends

Table 170. FIC Dual-target Drugs Market Drivers

Table 171. FIC Dual-target Drugs Market Challenges

Table 172. FIC Dual-target Drugs Market Restraints

Table 173. Research Programs/Design for This Report

Table 174. Key Data Information from Secondary Sources

Table 175. Key Data Information from Primary Sources

Table 176. Authors List of This Report

List of Figures

Figure 1. Product Picture of FIC Dual-target Drugs

Figure 2. Global FIC Dual-target Drugs Market Value by Type (US$ Million), 2021–2032

Figure 3. Global FIC Dual-target Drugs Market Share by Type: 2025 & 2032

Figure 4. EZH2/HSP90 Targets Product Picture

Figure 5. GPX4/CDK Targets Product Picture

Figure 6. Polθ/PARP Targets Product Picture

Figure 7. Others Product Picture

Figure 8. Global FIC Dual-target Drugs Market Value by Application (US$ Million), 2021–2032

Figure 9. Global FIC Dual-target Drugs Market Share by Application: 2025 & 2032

Figure 10. Hospital

Figure 11. Clinic

Figure 12. Other

Figure 13. Global FIC Dual-target Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global FIC Dual-target Drugs Market Size (US$ Million), 2021–2032

Figure 15. Global FIC Dual-target Drugs Sales (K Units), 2021–2032

Figure 16. Global FIC Dual-target Drugs Average Price (US$/Unit), 2021–2032

Figure 17. FIC Dual-target Drugs Report Years Considered

Figure 18. FIC Dual-target Drugs Sales Share by Manufacturers in 2025

Figure 19. Global FIC Dual-target Drugs Revenue Share by Manufacturers in 2025

Figure 20. Top 5 and Top 10 Global FIC Dual-target Drugs Players: Market Share by Revenue in FIC Dual-target Drugs in 2025

Figure 21. FIC Dual-target Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 22. Global FIC Dual-target Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 23. North America FIC Dual-target Drugs Sales Market Share by Country (2021–2032)

Figure 24. North America FIC Dual-target Drugs Revenue Market Share by Country (2021–2032)

Figure 25. United States FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 26. Canada FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 27. Europe FIC Dual-target Drugs Sales Market Share by Country (2021–2032)

Figure 28. Europe FIC Dual-target Drugs Revenue Market Share by Country (2021–2032)

Figure 29. Germany FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 30. France FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 31. U.K. FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Italy FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 33. Russia FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Asia Pacific FIC Dual-target Drugs Sales Market Share by Region (2021–2032)

Figure 35. Asia Pacific FIC Dual-target Drugs Revenue Market Share by Region (2021–2032)

Figure 36. China FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. Japan FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. South Korea FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. India FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Australia FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. China Taiwan FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Southeast Asia FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Latin America FIC Dual-target Drugs Sales Market Share by Country (2021–2032)

Figure 44. Latin America FIC Dual-target Drugs Revenue Market Share by Country (2021–2032)

Figure 45. Mexico FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Brazil FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. Argentina FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Colombia FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Middle East and Africa FIC Dual-target Drugs Sales Market Share by Country (2021–2032)

Figure 50. Middle East and Africa FIC Dual-target Drugs Revenue Market Share by Country (2021–2032)

Figure 51. Turkey FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Saudi Arabia FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. UAE FIC Dual-target Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Global Sales Market Share of FIC Dual-target Drugs by Type (2021–2032)

Figure 55. Global Revenue Market Share of FIC Dual-target Drugs by Type (2021–2032)

Figure 56. Global FIC Dual-target Drugs Price (US$/Unit) by Type (2021–2032)

Figure 57. Global Sales Market Share of FIC Dual-target Drugs by Application (2021–2032)

Figure 58. Global Revenue Market Share of FIC Dual-target Drugs by Application (2021–2032)

Figure 59. Global FIC Dual-target Drugs Price (US$/Unit) by Application (2021–2032)

Figure 60. FIC Dual-target Drugs Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions